Human iPSC-derived macrophages for efficient Staphylococcus aureus clearance in a murine pulmonary infection model.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
14 12 2021
14 12 2021
Historique:
received:
26
03
2021
accepted:
08
09
2021
pubmed:
15
10
2021
medline:
7
1
2022
entrez:
14
10
2021
Statut:
ppublish
Résumé
Primary or secondary immunodeficiencies are characterized by disruption of cellular and humoral immunity. Respiratory infections are a major cause of morbidity and mortality among immunodeficient or immunocompromised patients, with Staphylococcus aureus being a common offending organism. We propose here an adoptive macrophage transfer approach aiming to enhance impaired pulmonary immunity against S aureus. Our studies, using human-induced pluripotent stem cell-derived macrophages (iMφs), demonstrate efficient antimicrobial potential against methicillin-sensitive and methicillin-resistant clinical isolates of S aureus. Using an S aureus airway infection model in immunodeficient mice, we demonstrate that the adoptive transfer of iMφs is able to reduce the bacterial load more than 10-fold within 20 hours. This effect was associated with reduced granulocyte infiltration and less damage in lung tissue of transplanted animals. Whole transcriptome analysis of iMφs compared with monocyte-derived macrophages indicates a more profound upregulation of inflammatory genes early after infection and faster normalization 24 hours postinfection. Our data demonstrate high therapeutic efficacy of iMφ-based immunotherapy against S aureus infections and offer an alternative treatment strategy for immunodeficient or immunocompromised patients.
Identifiants
pubmed: 34649271
pii: 477312
doi: 10.1182/bloodadvances.2021004853
pmc: PMC9153022
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5190-5201Subventions
Organisme : European Research Council
ID : 852178
Pays : International
Informations de copyright
© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Nat Immunol. 2020 Jun;21(6):636-648
pubmed: 32424365
Stem Cells Transl Med. 2013 Apr;2(4):274-83
pubmed: 23515118
Invest Ophthalmol Vis Sci. 2006 Nov;47(11):4926-30
pubmed: 17065508
Br Med Bull. 2016 Jun;118(1):50-63
pubmed: 26983962
Am J Respir Crit Care Med. 2005 Aug 15;172(4):427-32
pubmed: 15937293
Immunol Rev. 2015 Mar;264(1):182-203
pubmed: 25703560
Stem Cell Reports. 2017 Feb 14;8(2):334-345
pubmed: 28111278
Methods Mol Biol. 2014;1149:773-91
pubmed: 24818949
J Bacteriol. 2008 Jan;190(1):300-10
pubmed: 17951380
J Clin Immunol. 2018 Jan;38(1):13-27
pubmed: 29086100
Br J Pharmacol. 2006 Aug;148(8):1067-75
pubmed: 16783405
Adv Microb Physiol. 2014;65:125-202
pubmed: 25476766
Front Immunol. 2020 Jun 04;11:1016
pubmed: 32582159
Cell. 2010 Mar 19;140(6):805-20
pubmed: 20303872
Front Immunol. 2018 Mar 09;9:429
pubmed: 29593714
Mamm Genome. 2018 Aug;29(7-8):603-617
pubmed: 30094507
Nat Immunol. 2002 Apr;3(4):392-8
pubmed: 11896392
Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2390-5
pubmed: 21262803
Am J Respir Crit Care Med. 2003 Jan 15;167(2):103-4
pubmed: 12524246
Bull Eur Physiopathol Respir. 1977 Jan-Feb;13(1):57-67
pubmed: 321054
Science. 2012 Apr 6;336(6077):86-90
pubmed: 22442384
FEMS Microbiol Rev. 2017 Mar 1;41(2):139-157
pubmed: 27965320
Exp Hematol. 2013 Aug;41(8):742-8
pubmed: 23618622
Nat Biotechnol. 2019 Mar;37(3):252-258
pubmed: 30778232
J Immunol. 2001 Feb 15;166(4):2727-33
pubmed: 11160338
J Pediatr. 1997 Mar;130(3):378-87
pubmed: 9063412
Front Immunol. 2021 Mar 11;12:654406
pubmed: 33777053
Am Rev Respir Dis. 1990 Feb;141(2):471-501
pubmed: 2405761
Nat Commun. 2018 Nov 30;9(1):5088
pubmed: 30504915
Immunity. 2017 Jul 18;47(1):183-198.e6
pubmed: 28723550